Global Urodynamic Equipment and Consumables Market - 2022-2029
The Global Urodynamic Equipment and Consumables Market is expected to grow at a CAGR of 6% during the forecasting period (2022-2029).
Urodynamic testing, often known as urodynamics evaluates how well the bladder and urethra do their functions of collecting and releasing urine. Urologists and urogynecologists are the most common people that perform urodynamics. It gives the doctor the information he or she needs to diagnose the reason and nature of a patient's incontinence and recommend the best treatment alternatives.
Increasing clinical trials by the market players for the urodynamic equipment is expected to drive market growth.
UroMonitor is an intravenous TAUM device that acts like a Fitbit for the bladder. It is simple to deploy and retrieve, requires no incisions or invasion of the bladder muscle, is more comfortable for patients, and provides us with a far better perspective of what happens in the patient's everyday life, allowing us to make a more accurate diagnosis. It has the potential to revolutionize urology and the identification of urinary tract problems in the lower urinary tract. Similarly, it is introduced into a patient's bladder lumen by a simple office procedure that is similar to cystoscopy or catheter placement. It collects physiological data over a four- to seven-day period and wirelessly communicates it to the patient's electronic data recorder to aid in diagnosis and clinical care by their physician. The patient can then remove the device with a string and dispose of it properly, or their urology team can remove it in the office. As a result, UroMonitor is presently undergoing preliminary clinical trials to see if it has the same or similar effects as normal urodynamic testing. Thus, from the above statements, the market is expected to drive in the forecast period.
The high cost of equipment and availability of alternative treatment for urinary incontinence is expected to hamper the market growth in the forecast period.
The COVID-19 pandemic has moderately impacted healthcare systems and the market. The impact of the COVID-19 pandemic on urological practice in the United States, as well as insights on the health-care delivery disruptions seen in this multimodal medical specialty. While clinical visits initially increased and then fell, the frequency of surgical operations reduced significantly over the period studied, and the use of numerous diagnostic procedures remained below baseline, potentially affecting patient outcomes in the future. Moreover, the AQUA Registry and new data resources in other specialties are required to evaluate the short- and long-term repercussions of the COVID-19 pandemic on health care delivery in the United States.
Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.
The uroflowmetry equipment segment is expected to dominate in 2021. The segment's growth is beneficial because it allows healthcare providers to monitor the amount and length of urine flow as well as the urinary tract's functionality. Moreover, when paired with additional tests such as a cystometrogram, it can detect obstructions such as an enlarged prostate or a weak bladder. Therefore, it has increased the demand for Uroflowmetry Equipment. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.
In 2021, North America accounted for the highest revenue share. The increasing prevalence of urinary disorders, the rising geriatric population, and key industry players increasing their R&D activity, which has resulted in several technological breakthroughs in the region are some of the factors the market is expected to boost in the forecast period. For instance, according to the American Urological Association, Urinary incontinence affects a quarter to a third of men and women in the United States. That's millions of people in the United States. Overactive bladder (commonly known as OAB) affects about 33 million people, causing symptoms such as urgency, frequency, and urge incontinence. Moreover, Urinary incontinence is associated with aging, and men who have prostate problems are also at increased risk. Some medications are linked to urinary incontinence and some medicines make it worse.
Additionally, Laborie Medical Technologies Inc., a medical technology business, stated in June 2021 that the first Optilume treatments were done at a UK NHS Trust. Optilume is a drug-coated balloon (DCB) technology that is utilized in the treatment of benign prostatic hyperplasia (BPH) and urethral structures. It has received CE Mark clearance for use in urethral strictures. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.
Major key players in the urodynamic equipment and consumables market are: Boston Scientific Corporation, Malvern Medical Developments Ltd, Zhejiang Chuangxiang Medical Technology Co., Ltd., HC Italia srl , Ev.Service Italia srl, Laborie Medical Technologies Corp., EMS Biomedical, The Prometheus Group, Stericom / P3 Medical and Amecath Medical Technologies.
Laborie is a global medical technology company specializing in Gastroenterology, Urology & Urogynecology, and Obstetrics, Gynecology & Neonatal. The company manufactures and delivers high-quality, high-impact diagnostic and therapeutic products that help clinicians and hospitals improve patient outcomes through progressive technology and best practice.
Nexam Pro Urodynamics System: Nexam Pro is an easy-to-use, comprehensive system that offers unique flexibility and modularity, ideal for both routine clinical urodynamics and research.
The global urodynamic equipment and consumables market report would provide an access to an approx. 45+ market data table, 40+ figures and 190 pages.
LIST NOT EXHAUSTIVE